Teva fails to reclassify MS drug to thwart generics
05-01-2021
Photo: Courtesy of Teva
Pharmaceutical company Teva has bought Allergan Generics from drugs business Allergan in a $40.5 billion deal.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Teva; Allergan; Allergan Generics; ANDA; generics; mergers and acquisitions; Erez Vigodman; Brent Saunders; FDA; Actavis
